Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting

Study acronym: CINV
StatusUnknown
PhasePhase 2
Started

Record status This record was last updated September 19, 2024 (before its estimated June 11, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Interventions: Active comparator (Drug), HSK21542-120μg (Drug), HSK21542-180μg (Drug) to Dolasetron (Drug), HSK21542 (Drug), HSK21542 (Drug)
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study title shortened, about 2 words
    v2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blind, active-controlled dose-finding study. About 180 subjects who receive a high emetic chemotherapy are planned to be enrolled and randomized into three groups by a ratio of 1:1:1.
Trial Details
NCT Number NCT06593782
Lead Sponsor First Affiliated Hospital of Wenzhou Medical University
Conditions
(from sponsor)		 Nausea and Vomiting, Chemotherapy-Induced
Related terms Nausea, Vomiting
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov